pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
787
stories
11d
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery
fiercebiotech
11d
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
fiercebiotech
11d
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
13d
CHMP endorses Eli Lilly’s GLP-1 pill and three other new drugs
endpoints
13d
Lilly interested in ibogaine investments, its neuro leader says
endpoints
14d
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
biopharma dive
14d
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
15d
Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
fiercebiotech
15d
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
fiercebiotech
15d
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
15d
Verastem cancer drug shows early promise in small study
biopharma dive
15d
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
biospace
15d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
16d
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
16d
STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine
stat
16d
Deep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
fiercebiotech
16d
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced
fiercebiotech
16d
Jazz CEO calls on industry to help rebuild momentum for leadership diversity
biospace
16d
STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds
stat
16d
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
16d
STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
stat
17d
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
biospace
17d
Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
fiercebiotech
17d
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
18d
GSK pledges $800M to add biologics production capabilities in Pennsylvania
biospace
19d
The 2026 Biotech Graveyard
fiercebiotech
20d
STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds
stat
20d
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
biopharma dive
20d
STAT+: Up and down the ladder: The latest comings and goings
stat
20d
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
← prev
page 3 of 27
next →
